These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 14343)

  • 1. [Inhibition of adrenergic beta receptors by N,N'-bis-[3-(2'ethoxyphenoxy)-2-hydroxypropyl]-ethylenediamine (Falirytmin) as compared to propranolol].
    Mentz P; Bayer BL; Wartner U; Terhaag B; Förster W
    Pharmazie; 1976; 31(9):640-2. PubMed ID: 14343
    [No Abstract]   [Full Text] [Related]  

  • 2. [Antiarrhythmic, cardiovascular and toxic actions of N,N'-bis-[3-(2'-ethoxyphenoxy)-2-hydroxypropyl]-ethlenediamine (Falirytmin) as compared to propranolol, quinidine and ajmaline].
    Terhaag B; Förster W
    Pharmazie; 1976; 31(9):635-9. PubMed ID: 1019213
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluation of beta-adrenolytic properties of N,N'-bis-(3-(p-methoxyphenoxy)-2-hydroxypropyl)-ethylenediamine and its N,N'-dimethyl derivative.
    Robak J; Grodzińska L
    Pol J Pharmacol Pharm; 1973; 25(3):253-7. PubMed ID: 4150018
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacology of a new beta-adrenoceptor blocking agent, The 15219.
    Caputi AP; Marmo E; Saini RK
    Res Commun Chem Pathol Pharmacol; 1972 Jul; 4(1):25-35. PubMed ID: 4152996
    [No Abstract]   [Full Text] [Related]  

  • 5. [Comparative studies on the question of differentiation of adrenergic beta-receptors].
    Mentz P; Bayer B; Wartner U; Förster W
    Arch Int Pharmacodyn Ther; 1970 Sep; 187(1):23-9. PubMed ID: 4394699
    [No Abstract]   [Full Text] [Related]  

  • 6. Quinterenol, a new beta adrenergic stimulant.
    Scriabine A; Moore PF; Iorio LC; Goldman IM; McShane WK; Booher KD
    J Pharmacol Exp Ther; 1968 Jul; 162(1):60-9. PubMed ID: 4385348
    [No Abstract]   [Full Text] [Related]  

  • 7. [Competitive antagonism between isoprenalin and adrenolytic agents toward urease].
    Mentz P; Förster W; Barth A; Gieszler C
    Arch Int Pharmacodyn Ther; 1973 Feb; 201(2):280-6. PubMed ID: 4146787
    [No Abstract]   [Full Text] [Related]  

  • 8. [Differentiation between beta adrenergic and Ca 2+ antagonistic influencing components of beta receptor blockaders in the myocardium and in smooth muscles with special reference to Trasicor].
    Grün G; Byon KY; Kaufmann R; Fleckenstein A
    Arztl Forsch; 1972 Nov; 26(11):369-78. PubMed ID: 4404592
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparative analysis of beta-1 adrenoceptor agonist and antagonist potency and selectivity of cicloprolol, xamoterol and pindolol.
    Hicks PE; Cavero I; Manoury P; Lefevre-Borg F; Langer SZ
    J Pharmacol Exp Ther; 1987 Sep; 242(3):1025-34. PubMed ID: 2888869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonary vascular and cardiac effects of glucagon before and after adrenergic beta-receptor blockade.
    Madan BR; Gupta RS; Jain BK
    Indian J Physiol Pharmacol; 1971 Oct; 15(4):173-7. PubMed ID: 4401547
    [No Abstract]   [Full Text] [Related]  

  • 11. Differences in pulmonary and cardiovascular beta receptors in the guinea pig and rabbit.
    Weissberg RM; Marian J; Bradshaw J; Alvarez R
    J Pharmacol Exp Ther; 1977 Aug; 202(2):337-45. PubMed ID: 18599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacology of new ethylenediamine derivatives (ROM-126, ROM-131, MK-142) with antiarrhythmic action. Part I. General pharmacological properties.
    Ernest K
    Pol J Pharmacol Pharm; 1975; 27(4):363-79. PubMed ID: 241067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Failure of propranolol to antagonize halothane depression of the uterus.
    Zauder HL; Pauerstein CJ; Fremming BD; Filner B
    Anesth Analg; 1970; 49(6):948-56. PubMed ID: 4397094
    [No Abstract]   [Full Text] [Related]  

  • 14. New N-isopropyl and N-tert.-butyl-phenoxypropanolaminic derivatives having -adrenolytic, anti-arrhythmic and local anaesthetic activity.
    Marmo E; Caputi AP; Saini RK
    Arzneimittelforschung; 1972 Jul; 22(7):1109-17. PubMed ID: 4404342
    [No Abstract]   [Full Text] [Related]  

  • 15. The in vivo effects of beta adrenergic stimulation and blockade on the human uterus at term.
    Mahon WA; Reid DW; Day RA
    J Pharmacol Exp Ther; 1967 Apr; 156(1):178-85. PubMed ID: 6023594
    [No Abstract]   [Full Text] [Related]  

  • 16. Potentiation of leukotriene C4 bronchoconstriction by beta-adrenoceptor antagonists in the guinea pig.
    Bongrani S; Razzetti R; Folco GC; Schiantarelli P
    Adv Prostaglandin Thromboxane Leukot Res; 1983; 12():173-8. PubMed ID: 6303085
    [No Abstract]   [Full Text] [Related]  

  • 17. [Pharmacological studies with 1-isopropylamino-3-(o-allyloxyphenoxy)-2-propanol-hydrochloride, an adrenergic beta-receptor blocking agent].
    Brunner H; Hedwall PR; Meier M
    Arzneimittelforschung; 1968 Feb; 18(2):164-70. PubMed ID: 5695373
    [No Abstract]   [Full Text] [Related]  

  • 18. [Experimental analysis of the cardiovascular effects of acebutolol, a drug with beta-adrenolytic activity].
    Marmo E; Rossi F; Lampa E; Chieppa S; Apolito A; Del Vecchio F
    Arch Sci Med (Torino); 1978; 135(1):57-78. PubMed ID: 25058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the adrenergic receptor blocking properties of 1-(4'-methylphenyl)-2-isopropylamino-propanol-HCl and propranolol.
    Levy B
    J Pharmacol Exp Ther; 1967 Jun; 156(3):452-62. PubMed ID: 6067476
    [No Abstract]   [Full Text] [Related]  

  • 20. Beta-adrenoreceptor blocking properties of new thienylethanolamine derivatives.
    Darias V; Madroñero R; del Río J
    Arzneimittelforschung; 1974 Nov; 24(11):1751-6. PubMed ID: 4155632
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.